BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), will present a LibiGel clinical update at the 2010 Annual Meeting of the International Society for the Study of Women’s Sexual Health (ISSWSH), being held from February 18-20, 2010 in St. Petersburg, Florida. Michael C. Snabes, MD, PhD, BioSante’s vice president of clinical development, will give a presentation entitled, “Low Cardiovascular Event Rate in Post-menopausal Women with Increased Cardiac Risk: Findings from the Ongoing Blinded LibiGel (testosterone gel) Cardiovascular and Breast Cancer Safety Study,” on Saturday February 20, 2010. BioSante is in Phase III development of LibiGel for the treatment of hypoactive sexual desire disorder (HSDD) in menopausal women under an FDA approved SPA (Special Protocol Assessment). BioSante is enrolling women in three Phase III clinical studies with a new drug application (NDA) planned for mid-2011. “There still is no FDA approved pharmaceutical product for the treatment of HSDD and it is clear from the extensive off-label use of drugs for HSDD that women need an approved therapy. We believe LibiGel can be first product to market for this unmet medical need.” said Dr. Snabes. The annual ISSWSH conference brings together physicians, other healthcare providers, researchers, investors and companies in a meeting dealing with all issues related to women’s sexual health including HSDD. About BioSante Pharmaceuticals, Inc. BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel ® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this news release that are not historical in nature, particularly those that utilize terminology such as “will,” “potential,” “continue,” “could,” “should,” “believe,” “can,” ”intends,” “plans,” “expects” or the negative of these words or other words of similar meaning, or future dates, are forward-looking statements. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; BioSante's need for and ability to obtain additional financing; the effect of general business and economic conditions; and risks arising from BioSante's merger with Cell Genesys. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its registration statement on Form S-4 filed in connection with the merger with Cell Genesys and BioSante's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. The information set forth in this news release speaks only as of the date hereof, and BioSante undertakes no obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.